SH reports grants from the Medical Research Council Clinical Academic Partnership (award MR/W030004/1), the Juvenile Diabetes Research Foundation International, the National Institute for Health and Care Research, Abbott UK (unrestricted educational), and Insulet (investigator initiated study); consulting fees from Roche; honoraria for lectures from Abbott UK, Insulet, Dexcom, Medtronic; has participated in advisory boards for Tandem, Dexcom, Medtronic, and Vertex; is a board member for the International Diabetes Federation; is Vice-Chair of the Association of British Clinical Diabetologist's Diabetes Technology Network; and is a member of the Diabetes UK Research Steering Group, Medical Advisor for Diabetes to the Secretary of the State for Transport. KB reports grants from the European Commission Horizon 2020 Program, Berlin Institute of Health (BIH) Digital Clinician Scientist Program, BIH/Wellcome Trust SPOKES Translational Partnership Fellowship, BIH QUEST Patient & Stakeholder Engagement Grant, ISPAD-JDRF Fellowship, Deutsche Diabetes Gesellschaft, and Honda Research Institute; consulting fees from the Diabetes Center Berne, Sanofi, Guidepoint, Medtronic and Dexcom; honoraria for lectures from Dedoc Labs, VDBD, Berliner Diabetesgesellschaft, Theras, Abbott UK, Novo Nordisk, Sanofi, and Next Convention; honoraria for manuscript writing from Kirchheim Verlag; has participated in scientific advisory boards for Dexcom and Medtronic; is Head of Medical for #dedoc°; is board member for the BIH Clinician Scientist Board; is member of the Commission for Equity Diversity and Inclusion of the Faculty of Charité—Universitätsmedizin Berlin (ChaKo); and is member and co-founder of the Allianz für Gleichstellung of Charité—Universitätsmedizin Berlin. SF reports grants from the Novo Nordisk Islet Stem Cell Programme, JDRF International, the Steve Morgan Foundation/Diabetes UK, Helmsley Charitable Foundation, British Heart Foundation, Medical Research Council, EastBio, and the Chief Scientist Office; consulting fees from the Novo Nordisk Stem Cell therapy Programme; patents (GB2313199.8, August 2023); is a member of the JDRF UK Scientific Committee; on the Novo Nordisk UK Research Foundation Board of Trustees; board member of the Danish Diabetes and Endocrinology Academy on Strategic Partnerships; member of the International Pancreas and Islet Transplantation Association Education Group; part of the Type 1 Diabetes Immunotherapy Consortium; member of JDRF International; and was previously member of the Diabetes UK, Clinical Studies Group, Lead Metabolic and Obesity Networks, Society for Endocrinology, and Society for Endocrinology, Council of Health Care Professionals. PAS holds the Charles A Allard Chair in Diabetes Research; is supported by the Academic Medicine and Health Services Program; reports consulting fees from Vertex and Novo Nordisk; honoraria for presentations from Vertex; travel expenses to attend ATTD from Vertex; and is Medical Director of the Clinical Islet Transplant Program, Alberta Health Services. We acknowledge the ongoing feedback from those under our clinical care and experts for their experience within our patient and public involvement groups in our research programs.